110
Participants
Start Date
February 11, 2025
Primary Completion Date
August 5, 2025
Study Completion Date
August 5, 2025
Teplizumab
This study will not administer any treatment, only observe the treatment as prescribed in real-world clinical practice.
Hassenfeld Children's Hospital at NYU Langone, New York
Morgan Stanley Children's Hospital, New York
Ten's Medical PC, Staten Island
SUNY Upstate Medical University PARENT, Syracuse
Children's National Medical Center, Washington D.C.
Atlanta Diabetes Associates, Atlanta
Childrens Healthcare of Atlanta, Atlanta
Doctor's Clinic, Vero Beach
University of Miami Medical Center, Miami
USF Diabetes Center, Tampa
Vanderbilt University Medical Center, Nashville
AM Diabetes & Endocrinology Center, Bartlett
University of Louisville, Louisville
Riley Hospital for Children, Carmel
Sheba Medical Center, Ramat Gan
Sanford Research/USD, Fargo
Arkansas Children's Hospital Research Institute, Little Rock
University of Texas Southwestern Medical Center, Dallas
Barbara Davis Center For Childhood Diabetes, Aurora
Diabetes and Endocrine Treatment Specialists, Sandy City
University of Utah Hospitals & Clinics, Salt Lake City
University of California, San Francisco, San Francisco
Schneider Children's Medical Center, Petah Tikva
Tel Aviv Sourasky Medical Center, Tel Aviv
Boston Children's Hospital Division of Endocrinology, Boston
Atlantic Health, Morristown
El Paso Medical Research Institute, El Paso
Lead Sponsor
Sanofi
INDUSTRY